CA2285490C - Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries - Google Patents
Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries Download PDFInfo
- Publication number
- CA2285490C CA2285490C CA002285490A CA2285490A CA2285490C CA 2285490 C CA2285490 C CA 2285490C CA 002285490 A CA002285490 A CA 002285490A CA 2285490 A CA2285490 A CA 2285490A CA 2285490 C CA2285490 C CA 2285490C
- Authority
- CA
- Canada
- Prior art keywords
- carnitine
- taurine
- patients
- heart
- cardiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000016709 nutrition Nutrition 0.000 title abstract description 17
- 230000002438 mitochondrial effect Effects 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 title description 12
- 230000035764 nutrition Effects 0.000 title description 10
- 230000001413 cellular effect Effects 0.000 title description 9
- 230000006872 improvement Effects 0.000 title description 7
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 130
- 229960003080 taurine Drugs 0.000 claims abstract description 65
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 49
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 46
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 41
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 19
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 15
- 229940035936 ubiquinone Drugs 0.000 claims description 24
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 17
- 241000282412 Homo Species 0.000 claims description 13
- 208000019622 heart disease Diseases 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 13
- 230000032683 aging Effects 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 8
- 241000282326 Felis catus Species 0.000 claims description 7
- 230000006866 deterioration Effects 0.000 claims description 7
- 241000282472 Canis lupus familiaris Species 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 230000037147 athletic performance Effects 0.000 claims description 4
- 230000002232 neuromuscular Effects 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 abstract description 64
- 229960004203 carnitine Drugs 0.000 abstract description 45
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract description 38
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 abstract description 28
- 235000019157 thiamine Nutrition 0.000 abstract description 26
- 239000011721 thiamine Substances 0.000 abstract description 26
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 23
- 235000018102 proteins Nutrition 0.000 abstract description 20
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 108090000623 proteins and genes Proteins 0.000 abstract description 20
- 229960003624 creatine Drugs 0.000 abstract description 19
- 239000006046 creatine Substances 0.000 abstract description 19
- 230000009469 supplementation Effects 0.000 abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 15
- 230000005856 abnormality Effects 0.000 abstract description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 13
- 235000018417 cysteine Nutrition 0.000 abstract description 13
- 235000019165 vitamin E Nutrition 0.000 abstract description 13
- 239000011709 vitamin E Substances 0.000 abstract description 13
- 229930003427 Vitamin E Natural products 0.000 abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 12
- 229940046009 vitamin E Drugs 0.000 abstract description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 6
- 235000011649 selenium Nutrition 0.000 abstract description 6
- 229910052711 selenium Inorganic materials 0.000 abstract description 6
- 239000011669 selenium Substances 0.000 abstract description 6
- 238000012937 correction Methods 0.000 abstract description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract description 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 abstract description 3
- 229960001009 acetylcarnitine Drugs 0.000 abstract description 3
- 229960002433 cysteine Drugs 0.000 abstract description 2
- 229960000984 tocofersolan Drugs 0.000 abstract 1
- 239000002076 α-tocopherol Substances 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 description 43
- 210000002216 heart Anatomy 0.000 description 40
- 230000001965 increasing effect Effects 0.000 description 36
- 230000000747 cardiac effect Effects 0.000 description 26
- 230000002107 myocardial effect Effects 0.000 description 25
- 229960003495 thiamine Drugs 0.000 description 24
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 235000015097 nutrients Nutrition 0.000 description 23
- 210000002027 skeletal muscle Anatomy 0.000 description 23
- 239000013589 supplement Substances 0.000 description 23
- 230000036542 oxidative stress Effects 0.000 description 22
- 230000004064 dysfunction Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 210000004165 myocardium Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 17
- 241000699800 Cricetinae Species 0.000 description 17
- 239000011575 calcium Substances 0.000 description 17
- 229910052791 calcium Inorganic materials 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 230000008901 benefit Effects 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 208000002894 beriberi Diseases 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 208000005428 Thiamine Deficiency Diseases 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 208000002720 Malnutrition Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000000470 constituent Substances 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010007559 Cardiac failure congestive Diseases 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 210000000107 myocyte Anatomy 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 208000020446 Cardiac disease Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 6
- 229960003883 furosemide Drugs 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000006371 metabolic abnormality Effects 0.000 description 6
- 230000004220 muscle function Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 208000026278 immune system disease Diseases 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000037323 metabolic rate Effects 0.000 description 5
- 230000003387 muscular Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 230000002715 bioenergetic effect Effects 0.000 description 4
- 230000001756 cardiomyopathic effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 229940030606 diuretics Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000011785 micronutrient Substances 0.000 description 4
- 235000013369 micronutrients Nutrition 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- -1 that of carnitine Chemical compound 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- 206010058892 Carnitine deficiency Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001964 calcium overload Effects 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000006286 nutrient intake Nutrition 0.000 description 3
- 235000003715 nutritional status Nutrition 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 240000001879 Digitalis lutea Species 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010020674 Hypermetabolism Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000008425 Protein deficiency Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001201 calcium accumulation Effects 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000002346 musculoskeletal system Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003617 peroxidasic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102000004482 ATP Translocases Mitochondrial ADP Human genes 0.000 description 1
- 108010017236 ATP Translocases Mitochondrial ADP Proteins 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010059186 Early satiety Diseases 0.000 description 1
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 1
- 101710119049 Glutathione peroxidase 3 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010026865 Mass Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010074253 Phosphatidyl-N-Methylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 108010030678 Phosphatidylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- 102100028873 Sodium- and chloride-dependent taurine transporter Human genes 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011686 genetic mapping animal model Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000003365 myofibril Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000005737 synergistic response Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 108010017629 taurine transporter Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940004177 thiamine 25 mg Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002285490A CA2285490C (fr) | 1999-10-07 | 1999-10-07 | Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002285490A CA2285490C (fr) | 1999-10-07 | 1999-10-07 | Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2285490A1 CA2285490A1 (fr) | 2001-04-07 |
CA2285490C true CA2285490C (fr) | 2003-11-18 |
Family
ID=4164319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002285490A Expired - Lifetime CA2285490C (fr) | 1999-10-07 | 1999-10-07 | Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2285490C (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020076470A1 (en) | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
US8669282B2 (en) | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
US8592479B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals |
US20020115710A1 (en) * | 2000-10-31 | 2002-08-22 | Zicker Steven Curtis | Composition and method |
WO2005006878A1 (fr) * | 2003-07-07 | 2005-01-27 | Hill's Pet Nutrition, Inc. | Compositions permettant d'ameliorer le statut d'oxydation chez des animaux de compagnie |
WO2006071919A2 (fr) | 2004-12-29 | 2006-07-06 | Hill's Pet Nutrition, Inc. | Methodes permettant d'inhiber un declin des facultes d'apprentissage et/ou de la memoire chez les animaux |
CA2615060C (fr) | 2005-07-14 | 2016-06-21 | Hill's Pet Nutrition, Inc. | Procede permettant de prolonger la vie d'animaux |
-
1999
- 1999-10-07 CA CA002285490A patent/CA2285490C/fr not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2285490A1 (fr) | 2001-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6232346B1 (en) | Composition for improvement of cellular nutrition and mitochondrial energetics | |
US6080788A (en) | Composition for improvement of cellular nutrition and mitochondrial energetics | |
CA2284738C (fr) | Composition nutritionnelle servant a ameliorer la capacite energetique cellulaire | |
US6479069B1 (en) | Nutritional supplement for increased energy and stamina | |
ES2201451T3 (es) | Alimentos dieteticos para diabeticos. | |
Sole et al. | Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure | |
EP1087779B1 (fr) | Compositions permettant d'accroitre l'energie in vivo | |
Rebouche et al. | Carnitine metabolism and function in humans | |
US5977162A (en) | Therapeutic treatment for auditory function | |
US5571783A (en) | Composition and method for treating patients with hepatic disease | |
AU2002224848B2 (en) | Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition | |
US6562869B1 (en) | Nutritional supplement for increased energy and stamina | |
Guarnieri et al. | Carnitine metabolism in uremia | |
US5240961A (en) | Method of treating reduced insulin-like growth factor and bone loss associated with aging | |
Sole et al. | Conditioned nutritional requirements: therapeutic relevance to heart failure | |
EP0405295B1 (fr) | Formule alimentaire pour le traitement de maladies rénales | |
US20100124587A1 (en) | Creatine-containing vitamin and mineral composition | |
KR20010071467A (ko) | 글루타티온의 흡수 증가와 그것의 효과를 상승시키는데유용한 카르니틴과 글루타티온 함유 조성물 | |
CA2285490C (fr) | Composition pour ameliorer la nutrition des cellules et la capacite energetique des mitochondries | |
US6218420B1 (en) | Compositions based on aminoacids | |
AU2001270980B2 (en) | Food supplement with a slimming effect | |
US20200338153A1 (en) | Anaerobic antioxidant composition | |
RU2335927C2 (ru) | Обогащенные лейцином питательные композиции | |
KR100198159B1 (ko) | 체중 감량을 위한 조성물 | |
US20020077349A1 (en) | Method of treating age-related vision impairment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |